Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies

Delphine Planas; Timothee Bruel; Isabelle Staropoli; Florence Guivel-Benhassine; Francoise Porrot; Piet Maes; Ludivine Grzelak; Matthieu Prot; Said Mougari; Cyril Planchais; Julien Puech; Madelina Saliba; Riwan Sahraoui; Florent Femy; Nathalie Morel; Jeremy Dufloo; Rafael Sanjuan; Hugo Mouquet; Emmanuel Andre; Laurent Hocqueloux; Etienne Simon-Loriere; David Veyer; Thierry Prazuck; Helene Pere; Olivier Schwartz.
Preprint en Inglés | PREPRINT-BIORXIV | ID: ppbiorxiv-516888

Documentos relacionados

  1. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies.
  2. Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies.
  3. Serum neutralization of SARS-CoV-2 Omicron BA.2, BA.2.75, BA.2.76, BA.5, BF.7, BQ.1.1 and XBB.1.5 in individuals receiving Evusheld.
  4. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
  5. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
  6. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  7. Evaluating mAbs binding abilities to Omicron subvariant RBDs: implications for selecting effective mAb therapies.
  8. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
  9. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
  10. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic.